Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.

[1]  H. Itoh,et al.  Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease , 2019, Pharmaceutical Research.

[2]  J. Ware,et al.  Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects , 2018, Journal of clinical pharmacology.

[3]  Kumar A. Shah,et al.  UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions. , 2018, Bioanalysis.

[4]  Kayode Ogungbenro,et al.  Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation , 2018, Clinical pharmacology and therapeutics.

[5]  L. Dillen,et al.  Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  M. Otagiri,et al.  Parathyroid hormone contributes to the down‐regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF‐&kgr;B signaling pathway in secondary hyperparathyroidism , 2017, Biochemical pharmacology.

[7]  M. Otagiri,et al.  Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. , 2017, Kidney international.

[8]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[9]  D. Bednarczyk,et al.  Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  W. Humphreys,et al.  Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[11]  T. Nolin,et al.  Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  A. Tsubota,et al.  Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides , 2014, Antimicrobial Agents and Chemotherapy.

[13]  N. Nakamichi,et al.  Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans , 2013, Pharmaceutical Research.

[14]  R. Vanholder,et al.  A novel UPLC–MS–MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients , 2013, Analytical and Bioanalytical Chemistry.

[15]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[16]  F. Leblond,et al.  Effects of Chronic Renal Failure on Kidney Drug Transporters and Cytochrome P450 in Rats , 2011, Drug Metabolism and Disposition.

[17]  T. Nolin,et al.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam. , 2009, Journal of the American Society of Nephrology : JASN.

[18]  T. Nolin,et al.  Effect of hemodialysis on hepatic cytochrome P450 functional expression. , 2008, Journal of pharmacological sciences.

[19]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[20]  L. Benet,et al.  Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma. , 2006, Rapid communications in mass spectrometry : RCM.

[21]  Y Vanrenterghem,et al.  Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[23]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[24]  R. Kauppinen.  Porphyrias , 2005, The Lancet.

[25]  Hong Sun,et al.  EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN , 2004, Drug Metabolism and Disposition.